66 lncRNAs connected to the prognosis of LUAD.

The role of long noncoding RNAs (lncRNAs) has been verified by more and more researches in recent years. However, there are few reports on cellular senescence-associated lncRNAs in lung adenocarcinoma (LUAD). Therefore, to explore the prognostic effect of lncRNAs in LUAD, 279 cellular senescence-related genes, survival information and clinicopathologic parameters were derived from the CellAge database and The Cancer Genome Atlas (TCGA) database. Then, we constructed a novel cellular senescence-associated lncRNAs predictive signature (CS-ALPS) consisting of 6 lncRNAS (AC026355.1, AL365181.2, AF131215.5, C20orf197, GAS6-AS1, GSEC). According to the median of the risk score, 480 samples were divided into high-risk and low-risk groups. Furthermore, the clinicopathological and biological functions, immune characteristics and common drug sensitivity were analyzed between two risk groups. In conclusion, the CS-ALPS can independently forecast the prognosis of LUAD, which reveals the potential molecular mechanism of cellular senescence-associated lncRNAs, and provides appropriate strategies for the clinical treatment of patients with LUAD.近年来，越来越多的研究证实了长链非编码RNA（long noncoding RNAs，lncRNAs）的生物学功能。然而，目前针对肺腺癌（lung adenocarcinoma，LUAD）中细胞衰老相关长链非编码RNA的研究报道仍较为匮乏。因此，为探究长链非编码RNA在肺腺癌中的预后价值，本研究从细胞衰老基因数据库（CellAge）与癌症基因组图谱（The Cancer Genome Atlas，TCGA）中获取了279个细胞衰老相关基因、患者生存信息及临床病理参数。随后，本研究构建了一套由6个长链非编码RNA（AC026355.1、AL365181.2、AF131215.5、C20orf197、GAS6-AS1、GSEC）构成的新型细胞衰老相关长链非编码RNA预测特征（cellular senescence-associated lncRNAs predictive signature，CS-ALPS）。依据风险评分的中位数，将480例样本划分为高风险组与低风险组。此外，本研究还对比分析了两组样本的临床病理特征、生物学功能、免疫特征及常见药物敏感性差异。综上，该CS-ALPS可独立预测肺腺癌患者的预后，揭示了细胞衰老相关长链非编码RNA的潜在分子机制，同时为肺腺癌患者的临床治疗提供了合理的干预策略。